How to successfully commercialise microbiome-based diagnostics
In this Med-tech Innovation News article, Andrew Thomson, Brian Carpenter and Robert Broadnax explore key drivers of adoption of microbiome-based diagnostics,...
CRA’s life sciences litigation support services are grounded in a comprehensive understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 30 years, our experts have consulted with major life science companies, law firms, and regulatory agencies around the globe. We provide clients with the industry and analytical expertise needed to solve our clients’ most complex issues.
CRA has a reputation for delivering rigorous analysis and expert testimony. Economic expertise is complemented by experience assisting life sciences companies with business and policy issues. This combination allows CRA to provide effective expert testimony and support.
Engagements
- 01Economic analysis in a product hopping litigationThis case involved a blood thinner drug whose initial patent had expired. The brand company improved the product and obtained additional patents on those...View engagement
- 02Economic analysis of generic test specification standardsThis matter involved scientific tests for generic drug closeness to the brand, as required by the FDA. The plaintiff alleged deceptive conduct within the...View engagement
- 03Breach of a global co-marketing deal: Swiss arbitrationSituation: Our client, a major pharmaceutical manufacturer, had to prove damages from the wrongful termination of its global co-marketing/co-promotion rights...View engagement
Meet our team
![]()
Gregory K. BellGroup Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.com![]()
![]()